Compare Procter & Gamble Health with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs NOVARTIS - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH NOVARTIS PROCTER & GAMBLE HEALTH/
NOVARTIS
 
P/E (TTM) x 41.0 1,904.1 2.2% View Chart
P/BV x 4.4 25.3 17.3% View Chart
Dividend Yield % 10.8 1.7 620.1%  

Financials

 PROCTER & GAMBLE HEALTH   NOVARTIS
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
NOVARTIS
Mar-19
PROCTER & GAMBLE HEALTH/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs3,549980 362.1%   
Low Rs1,301600 216.8%   
Sales per share (Unadj.) Rs511.4198.7 257.3%  
Earnings per share (Unadj.) Rs61.321.0 292.3%  
Cash flow per share (Unadj.) Rs74.022.3 332.5%  
Dividends per share (Unadj.) Rs440.0010.00 4,400.0%  
Dividend yield (eoy) %18.11.3 1,433.5%  
Book value per share (Unadj.) Rs927.8307.5 301.7%  
Shares outstanding (eoy) m16.6024.69 67.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.74.0 119.3%   
Avg P/E ratio x39.637.7 105.0%  
P/CF ratio (eoy) x32.835.5 92.3%  
Price / Book Value ratio x2.62.6 101.7%  
Dividend payout %717.947.7 1,505.3%   
Avg Mkt Cap Rs m40,25719,508 206.4%   
No. of employees `0001.10.6 195.2%   
Total wages/salary Rs m1,3131,171 112.1%   
Avg. sales/employee Rs Th7,486.78,445.4 88.6%   
Avg. wages/employee Rs Th1,157.62,015.7 57.4%   
Avg. net profit/employee Rs Th897.2891.0 100.7%   
INCOME DATA
Net Sales Rs m8,4904,907 173.0%  
Other income Rs m244783 31.2%   
Total revenues Rs m8,7345,689 153.5%   
Gross profit Rs m1,482123 1,206.5%  
Depreciation Rs m21132 664.2%   
Interest Rs m016 0.0%   
Profit before tax Rs m1,514858 176.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m660-   
Tax Rs m563340 165.4%   
Profit after tax Rs m1,017518 196.5%  
Gross profit margin %17.52.5 697.3%  
Effective tax rate %37.139.6 93.7%   
Net profit margin %12.010.6 113.6%  
BALANCE SHEET DATA
Current assets Rs m15,3438,055 190.5%   
Current liabilities Rs m1,9601,850 106.0%   
Net working cap to sales %157.6126.4 124.7%  
Current ratio x7.84.4 179.8%  
Inventory Days Days4945 108.3%  
Debtors Days Days2834 83.9%  
Net fixed assets Rs m1,209150 807.3%   
Share capital Rs m166123 134.5%   
"Free" reserves Rs m15,2357,469 204.0%   
Net worth Rs m15,4017,592 202.9%   
Long term debt Rs m00-   
Total assets Rs m17,5959,824 179.1%  
Interest coverage xNM54.9-  
Debt to equity ratio x00-  
Sales to assets ratio x0.50.5 96.6%   
Return on assets %5.85.4 106.5%  
Return on equity %6.66.8 96.9%  
Return on capital %10.311.5 89.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,63658 2,840.8%   
Fx outflow Rs m4,3681,326 329.3%   
Net fx Rs m-2,732-1,269 215.3%   
CASH FLOW
From Operations Rs m-1,304-1,943 67.1%  
From Investments Rs m12,6972,742 463.0%  
From Financial Activity Rs m-301-298 100.8%  
Net Cashflow Rs m11,093501 2,212.8%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 51.8 75.0 69.1%  
Indian inst/Mut Fund % 18.2 2.0 910.0%  
FIIs % 1.0 1.6 62.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 21.5 135.3%  
Shareholders   28,591 41,647 68.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   PANACEA BIOTECH  DIVIS LABORATORIES  FULFORD INDIA  ALKEM LABORATORIES  AJANTA PHARMA  

Compare PROCTER & GAMBLE HEALTH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Falls 750 Points from Day's High; Telecom and Energy Stocks Witness Selling(Closing)

After opening the day on a strong note, Indian share markets witnessed selling pressure during closing hours today and ended flat.

Related Views on News

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (2QFY20); Net Profit Down 13.0% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 358 m (down 13.0% YoY). Sales on the other hand came in at Rs 2 bn (down 0.4% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

Smallcaps Are in a Sweet Spot Again: Are You Buying?(Profit Hunter)

Jul 3, 2020

This is why I believe smallcaps are the place to be in the near future.

How We Made 10%+ Profits Overnight(Fast Profits Daily)

Jul 3, 2020

A simple trade in natural gas delivered more than 10% overnight. Here's how we did it...

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Jul 15, 2020 (Close)

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH - ALEMBIC LTD COMPARISON

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS